Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

elranatamab-bcmm

View Patient Information
A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab-bcmm binds to both CD3 on T cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD3/anti-BCMA bispecific antibody PF-06863135
B-cell maturation antigen-CD3 bispecific antibody PF-06863135
BCMA x CD3 bispecific antibody PF-06863135
BCMA-CD3 bispecific Ab PF-06863135
elranatamab
US brand name:Elrexfio
Code name:PF 06863135
PF-06863135
PF06863135
RN 613
RN-613
RN613
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search